~~<i id='AA503CC9E6'><strike id='AA503CC9E6'><tt id='AA503CC9E6'><pre id='AA503CC9E6'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

hotspot

author：hotspot 2025-10-01 06:01:09 - browse：72365

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： UHS says company favors patients whose insurance pays more

focus

leisure time

focus

knowledge

leisure time

explore

AtableladenwithPPEandmedicalsuppliessuchassplitsponges,disposablebloodpressurecuffs,andgloves.DavidJ

WSS

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Rise in cancer among younger people worries and puzzles doctors

Digital health: a case of mistaken identity

A new crop of companies is reshaping the health data economy

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

entertainment

hotspot

focus

Medical records are filled with copy

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Cue Health, Covid

Activists slam private health insurers over coverage restrictions

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

Supreme Court strikes down use of affirmative action

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

What does generative AI mean for health care? We asked experts

Reports of telehealth's death have been greatly exaggerated

leisure time

In the gardens at Boston Children's Hospital, families find sanctuary

Roche’s Alnylam deal shows drug firms interested in heart drugs

What it's like to live with paralysis for one psychologist

For longer

As a primary care physician, here's how I hope to partner with AI

Making the case for fair compensation in clinical trials

focus

knowledge

leisure time

explore